Topical imiquimod therapy for basal and squamous cell carcinomas: A clinical experience

Cutis

Volumn 79, Issue 3, 2007, Pages 241-248

  Tillman Jr , Donald K ^a   Carroll, Marianne T ^b  

^a Great Plains Dermatology   (United States)

^b GENESYS REGIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOQUINOLINE DERIVATIVE; ANTINEOPLASTIC AGENT; IMIQUIMOD;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CASE REPORT; CURETTAGE; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADMINISTRATION, TOPICAL; ADULT; AGED; AGED, 80 AND OVER; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; CURETTAGE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 34147144925     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
2. Mikkilineni R, Weinstock MA. Epidemiology of skin cancer. In: Sober AJ, Haluska FG, eds. Atlas of Clinical Oncology: Skin Cancer. London, United Kingdom: BC Decker, Inc; 2001:1-15.
3. Gallagher RP, Hill GB, Bajdik CD, et al. Sunlight exposure, pigmentation factors, and risk of nonmelanocytic skin cancer, II: squamous cell carcinoma. Arch Dermatol. 1995;131:164-169.
4. Drake LA, Dinehart SM, Goltz RW, et al. Guidelines of care for Mohs micrographic surgery. American Academy of Dermatology. J Am Acad Dermatol. 1995;33(2 pt 1): 271-278.
5. Edens BL, Bartlow G A, Haghighi P, et al. Effectiveness of curettage and electrodesiccation in the removal of basal cell carcinoma. J Am Acad Dermatol. 1983;9: 383-388.
6. Suhge d'Aubermont PC, Bennett RG. Failure of curettage and electrodesiccation for removal of basal cell carcinoma. Arch Dermatol. 1984;120:1456-1460.
7. Oster-Schmidt C. Two cases of squamous cell carcinoma treated with topical imiquimod 5%. J Eur Acad Dermatol Venereol. 2004;18:93-95.
8. Mackenzie Wood A, Kossard S, de Launey J, et al. Imiquimod 5% cream in the treatment of Bowen's disease. J Am Acad Dermatol. 2001;44:462-470.
9. Arany I, Tyring SK, Stanley MA, et al. Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%. Antiviral Res. 1999;43:55-63.
10. Hemmi H, Kaisho T, Takeuchi O, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol. 2002;3: 196-200.
11. Miller RL, Gerster JF, Owens ML, et al. Imiquimod applied topically: a novel immune response modifier and new class of drug. Int J Immunopharmacol. 1999;21:1-14.
12. Lang PG, Maize JC Sr. Basal cell carcinoma. In: Rigel DS, Friedman RJ, Dzubow LM, et al, eds. Cancer of the Skin. 1st ed. Philadelphia, Pa: Elsevier Inc; 2005:101-132.
13. Nguyen TH, Yoon J. Squamous cell carcinoma. In: Rigel DS, Friedman RJ, Dzubow LM, et al, eds. Cancer of the Skin. 1st ed. Philadelphia, Pa: Elsevier Inc; 2005:133-150.
14. Salasche SJ. Curettage and electrodesiccation in the treatment of midfacial basal cell epithelioma. J Am Acad Dermatol. 1983;8:496-503.
15. Silverman MK, Kopf AW, Gladstein AH, et al. Recurrence rates of treated basal cell carcinomas, part 4: x-ray therapy. J Dermatol Surg Oncol. 1992;18:549-554.
16. Spencer JM, Tannenbaum A, Sloan L, et al. Does inflammation contribute to the eradication of basal cell carcinoma following curettage and electrodesiccation? Dermatol Surg. 1997;23:625-631.
17. Fink-Puches R, Soyer HP, Hofer A, et al. Long-term follow-up and histological changes of superficial non-melanoma skin cancers treated with topical deltaaminolevulinic acid photodynamic therapy. Arch Dematol. 1998;134:821-826.
18. Marks R, Gebauer K, Shumack S, et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol. 2001;44:807-813.
19. Beutner KR, Geisse JK, Helman D, et al. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol, 1999;41:1002-1007.
20. Cowen E, Mercurio MG, Gaspari AA. An open case series of patients with basal cell carcinoma treated with topical 5% imiquimod cream. J Am Acad Dermatol. 2002; 47(suppl 4):S240-S248.
21. Geisse JK, Rich P, Pandya A, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol. 2002;47:390-398.
22. Geisse J, Caro I, Lindholm J, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol. 2004;50:722-733.
23. Kagy MK, Amonette R. The use of imiquimod 5% cream for the treatment of superficial basal cell carcinomas in a basal cell nevus syndrome patient. Dermatol Surg. 2000;26:577-578.